| Recruitment status | Main results already published |
| Unique ID issued by UMIN | UMIN000007601 |
| Receipt No. | R000008979 |
| Official scientific title of the study | Multiinstitutional study on evaluation methods of renal function before and during chemotherapy for urothelial cancer |
| Date of disclosure of the study information | 2012/04/01 |
| Last modified on | 2018/05/30 (Ver. 9) |
| Basic information | ||
| Official scientific title of the study | Multiinstitutional study on evaluation methods of renal function before and during chemotherapy for urothelial cancer | |
| Title of the study (Brief title) | CURE study | |
| Region |
|
|
| Condition | ||
| Condition | Unresectable or metastatic urothelial carcinoma treated with systemic chemotherapy | |
| Classification by specialty |
|
|
| Classification by malignancy | Malignancy | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | In this retrospective study, using medical records of urothelial cancer patients, the various evaluation methods of renal function and cut off level for decision making will be extensively reviewed. This study is conducted to test the effect of each evaluation method and cut off level on protocol modification, treatment response, adverse events and survival outcome of patients treated with systemic chemotherapy. |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | The rate of dose modification in the 1st-line chemotherapy. |
| Key secondary outcomes | 1. The rate of regimen modification in the 1st-line chemotherapy.
2. Response rate in the 1st-line chemotherapy. 3. Overall survival rate. 4. Cancer-specific survival rate 5. Frequency of adverse effects. 6. Response rate in the 2nd-line chemotherapy. 7. Response rate in the 3rd-line chemotherapy. 8. Correlation among the measured results in renal function by different methods. |
| Base | |
| Study type | Observational |
| Study design | |
| Basic design | |
| Randomization | |
| Randomization unit | |
| Blinding | |
| Control | |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |
| No. of arms | |
| Purpose of intervention | |
| Type of intervention | |
| Interventions/Control_1 | |
| Interventions/Control_2 | |
| Interventions/Control_3 | |
| Interventions/Control_4 | |
| Interventions/Control_5 | |
| Interventions/Control_6 | |
| Interventions/Control_7 | |
| Interventions/Control_8 | |
| Interventions/Control_9 | |
| Interventions/Control_10 | |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1. Patients with histologically diagnosed urothelial carcinoma (*).
2. Patients with unresectable or metastatic urothelial carcinoma. 3. Patients treated with the 1st-line systemic chemotherapy from January 1, 2004 to December 31, 2010. 4. Aged 20 or older. *) Include ureteropelvic cancer which clinically diagnosed as urothelial carcinoma by cytologic and imaging diagnosis. |
|||
| Key exclusion criteria | 1. Patients given the first systemic chemotherapy before December 31, 2003.
2. Patients with active cancers in other organs at the start of systemic chemotherapy. |
|||
| Target sample size | 370 | |||
| Research contact person | |
| Name of lead principal investigator | Hiroyuki Nishiyama |
| Organization | Faculty of Medicine, University of Tsukuba |
| Division name | Department of Urology |
| Address | 1-1-1 Tennodai, Tsukuba, Ibaraki, Japan |
| TEL | 029-853-3196 |
| nishiuro@md.tsukuba.ac.jp | |
| Public contact | |
| Name of contact person | Daishi Ichioka |
| Organization | Faculty of Medicine, University of Tsukuba |
| Division name | Department of Urology |
| Address | 1-1-1 Tennodai, Tsukuba, Ibaraki, Japan |
| TEL | 029-853-3223 |
| Homepage URL | |
| daichioka@yahoo.co.jp | |
| Sponsor | |
| Institute | Department of Urology, Tsukuba University Hospital |
| Institute | |
| Department | |
| Funding Source | |
| Organization | University of Tsukuba |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | Japan |
| Other related organizations | |
| Co-sponsor | Tsukuba Clinical Research & Development Organization |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Main results already published | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Published |
| URL releasing results | https://academic.oup.com/jjco/article-lookup/doi/10.1093/jjco/hyv082 |
| Results | |
| Other related information | Retrospective cohort study |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000008979 |